乳腺癌已经从群体治疗走向个体化治疗,其中HER-2状态是判断患者生存预后的重要指标.如何准确判断HER-2状态以及确诊后早期阶段患者该如何选择靶向治疗,尽管已存在不少指南与共识,但仍然需要不断推广和普及.我们从HER-2状态的标准检测及靶向治疗的选择出发,阐述早期HER-2阳性乳腺癌患者的治疗准则与经验. Breast cancer has moved from group treatment to individualized treatment, and HER-2 status is an important index to judge the prognosis of patients.How to accurately determine the status of HER-2 and how to choose the targeted therapy in the early stage after diagnosis, although there are many Guidelines and consensus, but still need to continue to promote and popularize.We start from the standard test of HER-2 status and the choice of targeted therapy, we elaborate the treatment guidelines and experience of patients with early-stage HER-2 positive breast cancer.